PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143376
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143376
Whole Genome Amplification (WGA) Market size was valued at US$ 3,998.1 Million in 2025, expanding at a CAGR of 6.6% from 2026 to 2033.
Whole Genome Amplification (WGA) is a technique used in producing milligrams of DNA from a few milligrams of genomic DNA. WGA is very useful when there is limited source DNA, for example, single-cell DNA, a large biopsy, or a forensic sample. The resulting large quantity of genomic DNA is analyzed by processes such as sequencing, genotyping, and disease association studies. There are several methods of whole genome amplification, such as MDA (multiple displacement amplification) and DOP-PCR (degenerate oligonucleotide-primed PCR).
These methods produce accurate copies of the genome but can have some limitations such as allelic dropout or preferential amplification. It is essential to pick the right method as well as making sure that the input is good to ensure good downstream results, especially when the results will be used for clinical diagnosis. This technique enables comprehensive genomic analysis from limited DNA samples, supporting accurate downstream molecular applications.
Whole Genome Amplification (WGA) Market- Market Dynamics
Rising Disease Prevalence Requiring Genetic Diagnostics To Propel Market Demand
The rising prevalence of genetic disorders and chronic diseases is because of the high demand for genetic diagnoses due to the limitation of DNA samples, which require fast and efficient amplification to enable analysis of the genome and detection of the diseases and making use of evidence-based clinical decision-making. For example, in February 2026, according to the RARE portal org of Australia, there have been over 7,000 rare diseases recorded, and it was observed that 80 percent of these rare diseases are caused by genetics. According to estimations, there are over 2 million people in Australia who are suffering from rare diseases that impact their health and medical interventions. There has been an increase in rare diseases being identified through the use of technology such as genomics. This is mainly due to the fact that patients suffering from rare diseases face challenges in diagnosing themselves.
The Global Whole Genome Amplification (WGA) Market is segmented on the basis of Product Type, Application, End User, and Region.
In terms of product type, single-cell WGA kits represent a significant segment in the Whole Genome Amplification (WGA) market due to the efficiency they offer to amplify genomic DNA from single cells, helping in genetic analysis and application in single-cell genomics research. For instance, in March 2026, a study was published in Science about scalable semipermeable-capsule technology for high-throughput single-cell omics by NIH Gov, opening many opportunities for the following applications, such as single-cell genome sequencing, mRNA sequencing, digital PCR, single-cell RNA sequencing (scRNA-seq), and FACS-based transcriptome isolation.
Single Cell, Genome-Volume 391 Issue 6790 pp. 1138-1145, published on March 1st, 2026, by 11 researchers from 7 research institutions. It became clear from the mentioned study that single cells could be cultured and cloned and expanded for up to thirty days or more, and a scalable low-throughput process of single-cell preparation in microwells for CapSeq sequencing technology led to better capture rates for softer cell types. This advancement is expected to strengthen adoption of single-cell WGA kits across genomic research applications.
Whole Genome Amplification (WGA) Market- Geographical Insights
The Asia Pacific holds a notable position in the Whole Genome Amplification (WGA) market because of fast advancements in healthcare infrastructure along with increasing applications of precision medicine. For example, in March 2026, according to the Press Information Bureau (PIB), India is moving towards an era of personalised and precision medicine due to genomics and AI. The Genome India project has already sequenced the genome of 10,000 people with the intention to complete one million genomes in order to improve the area of preventive health care and disease prediction in India.
The genetic diversity of India is also very high, as the country's population has more than 4,000 to 5,000 communities. This makes the country ideal for conducting genomics research, precision healthcare, diagnostics, and personalised treatment. The objective of the Genome India project is to complete the sequencing of one million genomes of Indians. India is the third largest bio-manufacturing hub of the world. The government of India is promoting bio-foundries, bio-manufacturing hubs, and BioNEST incubators in India for the fast development of R&D in the area of biotechnology and health care. Rs. 1 lakh crore has been allotted for this purpose. This further enhances the prospects of Asia Pacific being the growth leader in genomics and precision medicine.
The Whole Genome Amplification (WGA) market is characterized by strong competition among leading life sciences and diagnostics companies, including Thermo Fisher Scientific Inc., QIAGEN N.V., Bio-Rad Laboratories Inc., Merck KGaA, and Takara Bio Inc. These companies manage to keep their presence on the market owing to their extensive WGA product portfolio, genomics technology, integration into workflows, collaborations, and effective distribution networks of different applications related to research, clinical, and molecular diagnostics. In June 2025, Thermo Fisher Scientific partnered with Regeneron Genetics Centre and its Olink Explore platform for the largest proteomics research study, which involves the processing of 200,000 patient samples, thus helping to advance genomic discovery and research of biomarkers. Such strategic alliances are anticipated to augment their capabilities in terms of innovation and market share.
In May 2025, QIAGEN acquired Genoox by paying $70 million cash in return for the acquisition of the Genoox Franklin cloud platform for the analysis of genetic testing and NGS data, including whole-exome and whole-genome sequencing, which became part of QIAGEN Digital Insights' product line.
In April 2025, Takara Bio showcased its Shasta(TM) Single-Cell System comprising the Shasta(TM) Whole-Genome Amplification Kit, which is an automated high-throughput single-cell WGA system capable of processing up to 1,500 cells at one time. The system was highlighted for oncology research and single-cell genomic analysis.